3-[2-(4-bromomethylene-7a-methyloctahydroinden-1-yl)propyl]-5-ethyl-2-phenethylisoxazolidine-5-carboxylic acid methyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-[2-(4-bromomethylene-7a-methyloctahydroinden-1-yl)propyl]-5-ethyl-2-phenethylisoxazolidine-5-carboxylic acid methyl ester
• 英文别名: methyl 3-[(2R)-2-[(1R,3aR,7aR)-4-(bromomethylidene)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-5-ethyl-2-(2-phenylethyl)-1,2-oxazolidine-5-carboxylate
• 化学式: C₂₉H₄₂BrNO₃
• 分子量: 532.561
• InChiKey: TUUUVELBKHVHTG-HETWJYQQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[2-(4-bromomethylene-7a-methyloctahydroinden-1-yl)propyl]-5-ethyl-2-phenethylisoxazolidine-5-carboxylic acid methyl ester 在 molybdenum hexacarbonyl 作用下， 以 acteonitrile 、 水 为溶剂， 反应 12.0h， 以53%的产率得到5-[2-(4-bromomethylene-7a-methyloctahydroinden-1-yl)propyl]-3-ethyl-3-hydroxy-1-phenethylpyrrolidine-2-one
  参考文献：
  名称：

  Synthesis and Biological Activities of VDR Antagonists; 25-Modified 1α,25-Dihdyroxyvitamin D3-26,23-lactam (DLAM) Derivatives

  摘要：

  Three series of DLAM (1 alpha,25-dihydroxyvitamin D-3-26,23-lactam) derivatives (9 compounds) with 25-modification were synthesized. The biological evaluation of these derivatives revealed that the bulkiness at the 25-position of the DLAM causes a decrease in both the binding affinity for VDR and antagonistic activity.

  DOI：

  10.3987/com-08-s(f)51
• 作为产物：
  描述：

  、 三甲基硅烷化重氮甲烷 在 咪唑 作用下， 以 甲醇 、 benezene 为溶剂， 反应 0.25h， 以269 mg的产率得到3-[2-(4-bromomethylene-7a-methyloctahydroinden-1-yl)propyl]-5-ethyl-2-phenethylisoxazolidine-5-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis and Biological Activities of VDR Antagonists; 25-Modified 1α,25-Dihdyroxyvitamin D3-26,23-lactam (DLAM) Derivatives

  摘要：

  Three series of DLAM (1 alpha,25-dihydroxyvitamin D-3-26,23-lactam) derivatives (9 compounds) with 25-modification were synthesized. The biological evaluation of these derivatives revealed that the bulkiness at the 25-position of the DLAM causes a decrease in both the binding affinity for VDR and antagonistic activity.

  DOI：

  10.3987/com-08-s(f)51